Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
03/2000
03/07/2000US6034256 Substituted benzopyran derivatives for the treatment of inflammation
03/07/2000US6034255 Inhibitors of cholesterol esterase
03/07/2000US6034250 Nitrone compounds
03/07/2000US6034246 Anticancer agent
03/07/2000US6034244 Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity
03/07/2000US6034242 2,4-pentadienoic acid derivatives having retinoid-like biological activity
03/07/2000US6034229 BMP-15 compositions
03/07/2000US6034134 1-Amino-alkylcyclohexane NMDA receptor antagonists
03/07/2000US6034127 Amidino protease inhibitors
03/07/2000US6034122 Combined use of diclofenac and tribenoside to treat osteoarthritis
03/07/2000US6034113 Derivatives of 1,3,4-oxadiazolone
03/07/2000US6034109 Method for protection of heart by limiting metabolic and ionic abnormalities developed during ischemia following ischemia or resulting from ischemia
03/07/2000US6034107 5-Substituted picolinic acid compounds and their production process
03/07/2000US6034098 Inhibitors of microsomal triglyceride transfer protein and method
03/07/2000US6034082 5-azabicyclo(3.1.0)hexylalkyl-2-piperiodones and --glutarimides as neurokinin receptor antagonists
03/07/2000US6034080 Alzheimer's disease
03/07/2000US6034077 4-substituted-3-(2-amino-2-cycloalkyl methyl)-acetamido azetidin-2-one derivatives as cysteine proteinase regulators
03/07/2000US6034072 Genetic engineering; anticancer, antitumor agent
03/07/2000US6034063 Human phosphatidylinositol transfer protein gamma
03/07/2000US6034061 Forming chondrocyte tissue in animal; administering bone morphogenic protein
03/07/2000US6034059 Treatment of catabolic states using authentic IGF-1 and hypocaloric amount of nutrients
03/07/2000US6034057 Cyclic octapeptide; antiarthritic agent
03/07/2000US6033869 Diagnosis, prevention, and treatment of disorders associated with aberrant cellular development and differentiation and inflammation.
03/07/2000US6033662 Oxygen activatable formulations for disinfection or sterilization
03/07/2000US6033655 Prepared by contacting a magnetic iron metal species with an ion exchange resin under conditions which permit binding between the metal and the resin
03/07/2000CA2030401C Inhibition of the abstinence syndrome
03/07/2000CA2013966C Active specific immunotherapy of adenocarcinomas producing immunosuppressive mucins
03/02/2000WO2000011478A1 Assays, methods and means for modulating nuclear localisation
03/02/2000WO2000011207A1 USE OF mCRP FOR DELIVERY OF MATERIALS INTO CELLS
03/02/2000WO2000011202A1 Cationic complexes of polymer-modified adenovirus
03/02/2000WO2000011194A1 Cyclophilin-type peptidyl-prolyl cis/trans isomerase
03/02/2000WO2000011174A1 Human il-1 epsilon dna and polypeptides
03/02/2000WO2000011169A2 Human cell signaling proteins (csig)
03/02/2000WO2000011033A2 Expression and export of angiostatin and endostatin as immunofusins
03/02/2000WO2000011019A1 Conjugates of dna interacting groups with steroid hormones for use as nucleic acid transfection agent
03/02/2000WO2000011018A1 Conjugates of dna interacting groups with steroid hormones for use as nucleic acid transfection agents
03/02/2000WO2000011011A1 3'-desoxypentopyranosyl nucleic acid, its production and its use
03/02/2000WO2000010997A1 Pyridyl ethers and thioethers as ligands for nicotinic acetylcholine receptor and its therapeutic application
03/02/2000WO2000010993A1 Diarylbenzopyran derivatives as cyclooxygenase-2 inhibitors
03/02/2000WO2000010982A1 Quinazoline derivatives and pharmaceutical applications therof
03/02/2000WO2000010981A1 Quinazoline derivatives
03/02/2000WO2000010980A1 Pyrimidinone derivatives for the treatment of atherosclerosis
03/02/2000WO2000010973A2 Oxo-pyridoimidazole-carboxamides: gaba brain receptor ligands
03/02/2000WO2000010967A1 Novel aryl sulphonamides and analogues
03/02/2000WO2000010609A1 Targeting of molecules to large vessel endothelium using epcr
03/02/2000WO2000010603A1 Compositions and methods for protecting organs, tissue and cells from immune system-mediated damage
03/02/2000WO2000010598A2 Recombinant botulinium toxin for the treatment of mucus hypersecretion
03/02/2000WO2000010594A1 The use of glial cell line-derived neurotrophic factor family-related compounds for regulating spermatogenesis and for preparing male contraceptives
03/02/2000WO2000010588A2 Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs
03/02/2000WO2000010563A1 Novel substituted triazole compounds
03/02/2000WO2000010553A2 Carbamate and urea compositions and neurotrophic uses
03/02/2000WO2000010551A2 Methods of using and compositions comprising dopamine reuptake inhibitors
03/02/2000WO2000010549A1 Regulation of substrate activity
03/02/2000WO2000010545A2 Use of substance p antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of nk-1 receptor antagonists for the treatment of chronic fatigue syndrome
03/02/2000WO2000010541A1 Stable spray-dried protein formulations
03/02/2000WO2000010529A1 Oral liquid mucoadhesive compositions
03/02/2000WO2000010528A1 Oral liquid mucoadhesive compositions
03/02/2000WO2000010526A2 New oral formulation for 5-ht4 agonists or antagonists
03/02/2000WO2000010507A2 Use of melanin for inhibition of angiogenesis and macular degeneration
03/02/2000WO1999065513A3 Pharmaceutical compositions for the treatment of helicobacter pylori-associated disorders
03/02/2000WO1999064059A3 Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders
03/02/2000WO1999064054A9 Multibinding inhibitors of topoisomerase
03/02/2000WO1999064043A9 Muscarinic receptor antagonists
03/02/2000WO1999063937A3 Multivalent macrolide antibiotics
03/02/2000WO1999063090A3 Protease inhibitor peptides
03/02/2000WO1999061614A3 Human socs proteins
03/02/2000WO1999058642A3 Secreted proteins and polynucleotides encoding them
03/02/2000WO1999058558A3 Cell signaling proteins
03/02/2000WO1999058555A3 Water-soluble pro-drugs of 2,6-diisopropylphenol analogues
03/02/2000WO1999057271A3 Feline cd80, feline cd86, feline cd28, and feline ctla-4 nucleic acid and polypeptides
03/02/2000WO1999057261A3 Human bmp-2 promoter and method for exploring bone-related substance by using the same
03/02/2000WO1999057149A3 Compounds and methods for modulating nonclassical cadherin-mediated functions
03/02/2000WO1999057146A9 Protein mixtures to induce therapeutic angiogenesis
03/02/2000WO1999056767A3 Method for treating cytokine mediated hepatic injury
03/02/2000WO1999045947A9 In vitro formation of congophilic maltese-cross amyloid plaques to identify anti-plaque therapeutics for the treatment of alzheimer's and prion diseases
03/02/2000WO1999042596A3 Phosphodiesterase 10
03/02/2000WO1999042088A3 Method for the treatment of diseases or disorders of the inner ear
03/02/2000WO1999036535A9 Apo-2 ligand
03/02/2000WO1998051662A3 Compounds and methods for the inhibition of the expression of vcam-1
03/02/2000DE19839499A1 2-Oxo-2H-chinolinderivate 2-oxo-2H-quinoline
03/02/2000DE19839337A1 Parenteral medicament for treating antithrombin III deficiency contains potent beta-isoform of antithrombin III
03/02/2000DE19814405C2 Porphyrine und ihre Verwendung als Photosensitizer Porphyrins and their use as photosensitizer
03/02/2000CA2342503A1 Quinazoline derivatives
03/02/2000CA2341989A1 Pyridyl ethers and thioethers as ligands for nicotinic acetylcholine receptor and its therapeutic application
03/02/2000CA2341903A1 Use of melanin for inhibition of angiogenesis and macular degeneration
03/02/2000CA2341586A1 Targeting of molecules to large vessel endothelium using epcr
03/02/2000CA2341558A1 Compositions and methods for protecting organs, tissue and cells from immune system-mediated damage
03/02/2000CA2341531A1 Oxo-pyridoimidazole-carboxamides: gaba brain receptor ligands
03/02/2000CA2341530A1 Carbamate and urea compositions and neurotrophic uses
03/02/2000CA2341516A1 Cationic complexes of polymer-modified adenovirus
03/02/2000CA2341370A1 Novel substituted triazole compounds
03/02/2000CA2341357A1 Quinazoline derivatives and pharmaceutical applications therof
03/02/2000CA2341309A1 Use of mcrp for delivery of materials into cells
03/02/2000CA2340928A1 Novel arylsulphonamides and analogues
03/02/2000CA2340785A1 Cyclophilin-type peptidyl-prolyl cis/trans isomerase
03/02/2000CA2339860A1 Human cell signaling proteins (csig)
03/02/2000CA2339537A1 Regulation of substrate activity
03/02/2000CA2338837A1 Assays, methods and means for modulating nuclear localisation
03/02/2000CA2338644A1 The use of glial cell line-derived neurotrophic factor family-related compounds for regulating spermatogenesis and for preparing male contraceptives
03/01/2000EP0982405A2 Recombinant alphavirus vectors
1 ... 1174 1175 1176 1177 1178 1179 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 ... 1564